What did Pacific Edge Limited announce?

Pacific Edge Limited (NZX: PEB) filed “Bell Potter Healthcare Conference 2026” with NZX on 16 November 2026, as an operational update announcement.

From the announcement:“New Zealand – Pacific Edge (NZX/ASX: PEB) today releases a presentation it is giving to the Bell Potter Healthcare Conference commencing today.”
When was it filed?
16 November 2026
Where is the original?
NZX announcement
Pacific Edge Limited logo

Bell Potter Healthcare Conference 2026

Operational Update16 November 2026PEBHealthcare

17 November 2026
BELL POTTER CONFERENCE PRESENTATION

DUNEDIN, New Zealand – Pacific Edge (NZX/ASX: PEB) today releases a presentation it is giving

to the Bell Potter Healthcare Conference commencing today.

The presentation is also available on Pacific Edge’s investor website (HERE)

ENDS

For more information:

Investors: Media:

Dr Peter Meintjes Richard Inder

Chief Executive The Project

Pacific Edge P: +64 21 645 643

P: +64 22 032 1263


OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way

in the development and commercialization of bladder cancer diagnostic and prognostic tests

for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in

Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its

wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of

urothelial cancer in patients presenting with hematuria and those being monitored for recurrent

disease. The tests help improve the overall patient experience, while prioritizing time and

clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than

twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American

Urological Association’s Microhematuria Guideline. To drive increased adoption and improved

patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies

designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and

South America. In the US, the test has been used by over 5,000 urologists who have ordered

more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the

population via public healthcare and all residents have the option of buying the test online.

---

Bell Potter Healthcare Conference
Dr Peter Meintjes

Chief Executive Officer

November 17, 2026

1

DR PETER MEINTJES
Chief Executive Officer

PRESENTING TODAY

2

This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its

activities at the date of this presentation).

A reference in this Important Notice and Disclaimer to the Information

means the information in this presentation and any verbal remarks made

by PEL directors or management(including answers to questions) in

respect of the matters addressed in this presentation.

Unless otherwise specified, the Information is stated at the date of this

presentation.The Information should be read in conjunction with PEL’s

Annual Report, half-year financial statements, and continuous disclosure

announcements released to NZX and ASX at

•www.nzx.com/companies/PEB; and

•https://www.asx.com.au/markets/company/PEB

Information of a general nature

The Information is of a general nature only and does not purport to be

complete or comprehensive. It does not contain all the information that

a person may require in evaluating or making an investment decision in

respect of PEL shares. Nor does it take into account any person’s

objectives or circumstances.

Not an offer

The Information is for informational purposes only. It is not an invitation

or offer of securities for subscription, purchase or sale for any purpose

or in any jurisdiction.

Not financial product advice

The Information does not constitute legal, financial, tax, investment, or

financial product advice, and is not a recommendation to invest in or

deal with PEL shares.

Past performance, including past PEL share price performance, cannot be

relied on as an indicator of future performance, including in respect of

PEL’s future financial performance, PEL’s future financial position, or

future PEL share price performance. Any investment in PEL shares is

subject to various risks, including those set out on pages 26 to 28 of

PEL’s Capital Raising Presentation that was released by NZX and ASX on

11 May 2026. If you are considering investing in or dealing with PEL

shares, you are encouraged to read those risks carefully, and to seek

your own professional advice, before you do so.

Forward-looking statements

The Information contains forward-looking statements that relate to

future events, outcomes or circumstances. Forward-looking statements,

by their very nature, are based on assumptions, estimates or

expectations about the future and involve inherent risks and

uncertainties. Many of those assumptions, estimates, expectations, risks

and uncertainties are matters that are beyond PEL’s control. There is no

assurance that any forward-looking statement will be realized or

achieved. Actual results or circumstances could differ (potentially

materially) from those statements.

Non-GAAP financial information

The Information contains certain financial measures that are “non-GAAP

financial information” under the New Zealand Financial Markets

Authority Guidance Note on disclosing non-GAAP financial information

and “non-IFRS financial information” under the ASIC Regulatory Guide on

disclosing non-IFRS financial information (and potentially under other

regulatory guidelines or rules).

Such financial information and financial measures do not have

standardized meanings prescribed under NZ IFRS or IFRS and therefore,

may not be comparable to similarly titled measures presented by other

entities, and should not be construed as an alternative to other financial

measures determined in accordance with NZ IFRS, or IFRS).

Currency

All dollar values to in the Information are in New Zealand dollars unless

otherwise stated.

Effect of rounding

A number of figures, amounts, percentages, estimates, calculations of

value and fractions in the Information are subject to the effect of

rounding. Accordingly, the actual calculations may differ.

Disclaimer

PEL has sought to use reasonable care to prepare the Information.

However, PEL and its related bodies corporate and affiliates, and their

respective directors, officers, partners, employees, agents, associates

and advisers (each such person, a PEL Person) do not make or provide

any representation, warranty or assurance, express or implied, of any

nature in respect of the Information (including, without limitation, as to

the accuracy, reliability or completeness of any of the Information or as

to whether any forward-looking statement will be realized or achieved or

the likelihood of this occurring).

No PEL Person is required or under any obligation to update this

presentation and, except where required by law or applicable Listing

Rules, no PEL Person is required or under any obligation to update the

Information.

To the maximum extent permitted by law, each PEL Person disclaims,

and no PEL Person shall have any, liability of any nature (including,

without limitation, arising from any fault or negligence) arising from or

in connection with (1) any person’s reliance on or use of the Information;

(2) any errors in or omissions from the Information; or (3) any failure to

update or correct the Information.

IMPORTANT NOTICE AND DISCLAIMER

3

INTRODUCTION TO PACIFIC EDGE
4

BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
THE STANDARD OF CARE – CYSTOSCOPY – IS HIGHLY INVASIVE, UNCOMFORTABLE AND COSTLY

5

1.Sievert et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Mar 7;27(3):295–300. doi: 10.1007/s00345-009-0395-z

2.World Cancer Research Fund. Statistics are from 2022. Growth due to aging population.

3.Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): Eur Urol 2012; 62: 118.

4.Source: Nursing Skills

5.Guldhammer et al (2024), “Cystoscopy Accuracy in Detecting Bladder Tumors: A Prospective Video-Confirmed Study.” Cancers. 2024;16(1):160. DOI: 10.3390/cancers16010160

6.Cxbladder Triage Plus Test Report, 07-QMS-091-US Rev A: NPV for scores below 0.15.

7.American Urological Association (AUA) 2025 Microhematuria Guideline.

B L A D D E R C A N C E R : A C O S T L Y , R E C U R R I N G D I S E A S E

1

st

Costliest cancer to treat on a

per-patient basis

1

6

th

Most common cancer in men

2

>50%

Recurrence, driving years of

repeat surveillance

3

TODAY’S STANDARD OF CARE

Cystoscopy: a scope into the bladder

A camera on the end of a scope is inserted

up the urethra to visually inspect the lining

of the bladder wall

4

Why it falls short

•Invasive and uncomfortable – patients defer or drop out of surveillance

•Costly, and consumes scarce urologist capacity

•Low yield – most patients scoped do not have cancer

•Have high variability between urologists, and only 81% sensitivity

5

I M P R O V E D : N O N-I N V A S I V E S T A N D A R D O F C A R E

Cxbladder: just pee in a cup

A simple urine test that detects and rules out bladder cancer –

no invasive cystoscopy required

99.4%

6

NPV: a negative result confidently rules out

cancer

Grade A Rating

7

AUA evidence rating in the 2025

Microhematuria Guideline

Why it solves the problem

•Collected at clinic or at home – no procedure, no discomfort

•Rules out cancer, reserving cystoscopy for those who need it

•Lower cost for payers and frees urologist capacity

ONE URINE SAMPLE, A CLEAR ANSWER AT EVERY STAGE OF CARE
CXBLADDER RULES OUT CANCER OR PRIORITIZES PATIENTS FOR CYSTOSCOPY

Symptoms

Hematuria (blood in urine)

The primary symptom of bladder

cancer, ~7m US patients a year

Disease management

Cxbladder Triage Plus testing

Rule out cancer or prioritize patients

for cystoscopy

Surgical intervention

TURBT – surgical resection

Tumor resected via cystoscope;

pathology confirms stage and grade

Surveillance

Cxbladder Monitor · Surveillance Plus

Monitor NMIBC patients for recurrence

1

Collect

Pee in a cup, at clinic or home

2

Analyze

Pacific Edge labs

Dunedin, NZ · Hershey, PA

RNA + DNA biomarkers, one

sample, Pacific Edge labs

3

Report

4

Interpret

LOW <0.15

De-intensify patient work-up

84.1% of patients; 0.6% risk of UC

INTERMEDIATE 0.15–0.54

Further clinical evaluation

9.5% of patients; 27.7% risk of UC

HIGH ≥0.54

Prioritize for cystoscopy

6.4% of patients; 74.6% risk of UC

THE PATIENT JOURNEY

THE PATIENT EXPERIENCE

Cxbladder Triage Plus

T E S T R E P O R T

0.05

LOW PROBABILITY

of urothelial carcinoma: 0.6%

95% CI (0.02 – 0.10)

LOW 0.6%27.7%74.6%

0.000.150.541.00

Sample result shown on the current Cxbladder Triage Plus report format. Not patient data.

TURBT: transurethral resection of a bladder tumor. NMIBC: non-muscle invasive bladder cancer. UC: Urothelial Carcinoma

6

DRIVING ECONOMIC VALUE FOR PATIENTS, CLINICIANS, HOSPITALS AND PAYERS
CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION, IMPROVED ACCESS AND ECONOMIC VALUE

TODAY: 100 microhematuria patients, all receive a cystoscopy

WITH CXBLADDER TRIAGE PLUS: 85 avoid cystoscopy

1

No cystoscopy, no cancerCystoscopy, no cancerCystoscopy, cancer

15% receive cystoscopy to find the same 5 cancer patients. Illustration assumes bladder cancer

incidence in microhematuria populations of 5%

2

85%

of cystoscopies safely

avoided

62%

of US counties don'thave

a registered urologist

4

13%

of high-risk patients

receive a cystoscopy

5

Patients

Low risk avoid an invasive, uncomfortable procedures,

high risk are prioritized for diagnostic cystoscopy

Clinicians

Confident rule-out (99.4% NPV) focuses cystoscopy on

patients most likely to have cancer

Hospitals

Urologists per person over 65 are falling

6

, potentially

delaying diagnosis. Cxbladder frees scarce capacity

Payers

Save >US$500 per patient

3

, as Medicare reimbursement

for cystoscopy declines

7

One urine test: better access, capacity and economics

1.Illustrative application of the observed risk distribution. Actual outcomes will vary, and no diagnostic test identifies every cancer

2.AUA Guidelines cite incidence of bladder cancer in microhematuria risk categories from 0.4-6%. 5% is an example

3.Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)

4.https://www.auanet.org/research-and-data/aua-census/census-results

5.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25048

6.Nam et al. (2021) Projected US Urology Workforce per Capita, 2020-2060 JAMA Network Open Published Online: November 16, 2021

7.https://www.cms.gov/medicare/physician-fee-schedule/search

7

US$10.6b
Global TAM

1

CXBLADDER MARKET OPPORTUNITY

CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY

~17m0.47m | 2.71m | 3.46m1.7m ~58k ~300k US$2.0b830m

~12m0.34m | 1.96m | 2.5m1.7m ~180k ~1mUS$1.9b600m

APAC

Primary growth

focus due to higher

CMS pricing

NZ market mature.

Australia and SEA in

business development

New market accessed

via IVD / kitted tests

1.Pacific Edge estimate combining US, APAC and Europe. See slides 31-33 for assumptions regarding eligible populations, testing frequency and pricing.

2.RDM: Residual Disease Monitoring

3.TRM: Therapeutic Response Monitoring

4.Management estimates derived from referred hematuria data in Woldu et al (2021), so do not add to ~7m figure for total incidence. See slides 36-38 for details.

All

hematuria

Microhematuria

4

Low | Intermediate | High

Gross

4


Hematuria

Annual cases of

bladder cancer

Living with bladder cancerTAMPopulation

SURVEILLANCE

(RDM

2

, TRM

3

, RECURRENCE)

PATIENT/DISEASE MANAGEMENT

(CLINICAL DECISION MAKING)

8

~7m0.20m | 1.14m | 1.46m0.7m ~90k ~750k US$6.7b340m

STRATEGY AND PROGRESS
9

10
MEDICARE: FINAL LCD COVERS TRIAGE AND TRIAGE PLUS

ACCESS TO ~71M LIVES SUBJECT TO LCD ELIGIBILITY CRITERIA

FINAL LCD (L40378): PUBLISHED 4 NOV 2026 | EFFECTIVE 20 DEC 2026

•Sole coverage: only Cxbladder Triage and Triage Plus are covered for intermediate-risk

microhematuria (~1.14m patients/year)

1

; competing tests and generic codes are non-covered

•Removes adoption barriers: eliminates reimbursement and logistical objections from

ordering clinicians

•Higher ASP

2

: Triage US$1,057 and Triage Plus US$1,328 per test, supporting revenue growth,

operating leverage and cashflow

•Medicare Advantage: expected to reimburse in line with Medicare policy, boosting cashflow

•Commercial payers: Medicare coverage can be leveraged to drive policy adoption and

appeals

~71M

Medicare lives

~2.8M

Microhematuria

opportunities / yr

1

US$1,328

Triage Plus price per test

“Cxbladder Triage has the most published evidence specific to

MH evaluation and is referenced in the AUA/SUFU 2025 guideline

as one option that may be considered for appropriately

counseled intermediate-risk patients...”

Novitas L40378, ‘Urine-based Biomarkers in Patients with

Microhematuria’

PATH FORWARD: EVIDENCE TO EXPAND COVERED INDICATIONS AT NEXT UPDATED LITERTURE REVIEW BY AUA

Q4 2026Q1 2027Q2 2027Q3 2027Q4 20272025

DRIVE - CV of Triage Plus

AUSSIE - CV of Triage Plus

microDRIVE - CV of Triage Plus

Pooled Analysis MH & GH - CV of Triage Plus

STRATA second publication - CU of Triage

AUA updated literature review - Expected window

Published Oct 2026

Published Nov 2025

1.Management estimate, see Slide 8.

2.Legacy tests had a Medicare approved price of US$760

CU = clinical utility; CV = clinical validity; MH = microhematuria; GH = gross hematuria

US PAYER CONVERSION: FROM POLICY TO CONTRACT
EFFECTIVE MEDICARE COVERAGE FROM 20 DECEMBER 2026 EXPECTED TO UNLOCK COMMERCIAL VOLUMES

11

1.Medicare, Blue Cross Blue Shield (BCBS) North and South Carolina and Kansas City Missouri, Hawaii Medical Services Association (Hawaii BCBS),Southern

California Permanente Medical Group (Kaiser SoCal), Sentara, Geisinger and MVP Healthcare

2.BCBS NC and SC, Kaiser SoCal and Medicare

3.Kaiser SoCal and Highmark

4.Kaiser SoCal

5.The figures represented are from Policy Reporter and are likely to be an underestimate of lives under policy and in-network due to some Insurers and their

subsidiaries administering government and other third-party programmes, not included in Policy Reporter.

US COMMERCIAL MARKET

MEDICARE AND FAVOURABLE MEDICAL

POLICY

MEDICARE AND IN-NETWORK CONTRACTS

SECURED

81.3m

Policy lives

1&5

78.6m

Contracted lives

2,5

4.9m

Contracted lives

4,5

223m

US private insured lives

Source: US Census

1,200

US private health insurance payers

Source: NAIC

71m

Medicare insured lives

Source: CMS

9.18m

VA covered lives

Source: VA

8.4m

Policy lives

3,5

CONVERTING POLICY AND CONTRACTING INTO REVENUE
INTEGRATED DELIVERY NETWORKS ARE OUR PRIORITY

12

1.Management estimates derived from referred hematuria data in Woldu et al (2021). See slides 36-38 for details.

2.Share of patient volume figures are management estimates

51%

30%

8%

7%

4%

Hospital Networks

Academic Centers

Veterans

Administration

Kaiser Permanente

Other

1.68m

INTEGRATED DELIVERY NETWORKSPRIVATE PRACTICE

2.8m

1

80%

20%

Large Urology

Group Practices

Community

Urology

1.12m

Low risk

80%20%

Intermediate risk

75%25%

High risk

34%66%

FemaleMale

60% of patient volume40% of patient volume

US SERVICEABLE MARKET

Medicare coverage is for

1.14m Intermediate Risk

PROVIDER MIX WITHIN CHANNEL

2

PROVIDER MIX WITHIN CHANNEL

2

AUA RISK CATEGORY BY SEX (AT BIRTH)

1.Net cash, cash equivalents and short-term deposits at the end of the period
2.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027

3.Management Estimates

4.Profitability threshold determined on an annualized basis across all products with a blended ASP >$NZD 1,450. Actual breakeven will vary with payer mix, collection rates, product mix and operating investment

13

Financial Period (NZ$M)

2H 26

(Unaudited)

1H 26

(Unaudited)

FY 26

(Audited)

2H 26 vs

1H 26

Operating Revenue$5.6$5.9$11.5(6.4%)

Total Revenue$6.5$7.1$13.6(9.3%)

Operating Expenses$23.1$26.2$49.4(11.9%)

Net Loss After Tax($16.7)($19.1)($35.8)(12.8%)

Net Cash Flows to Operating

Activities

($12.9)($19.0)($31.9)(32.1%)

Net Cash

1

$7.8$22.1$7.8(64.8%)

Monthly Cash Burn $2.4$3.3$2.9(27.7%)

Key milestones on our path to profitability:

NZ$36.1m raised

Raise completed in June 2026

Cash Burn <$2.5m/month

2H26 burn of NZ$2.4m/month, cash preservation

measures continued

20 December 26

Final LCD

Jan 2028

3

Surveillance Plus claims

(targeted)

~55,000 tests/yr

4

Profitability breakeven

FINANCIALS AND PATH TO PROFITABILITY

COST DISCIPLINE PRESERVES THE UPSIDE AS MEDICARE COVERAGE APPROACHES

US pricing increases from 1 Jan 2027

Triage Plus US$1,328; Triage US$1,057

2

(↑39%)

Monitor US$1,026

2

(↑35%)

14
PACIFIC EDGE CATALYSTS FOR LONG-TERM SUSTAINABLE GROWTH

1

AN EXPANDING SERVICEABLE MARKET AND REVENUE

1

Medicare coverage

high-risk Microhematuria

2

Surveillance Plus

launched

3

Medicare coverage

Gross Hematuria patients

4

Kitted RUO

2

launch

5

Kitted IVD

3

launch

6

New product

launch

N E A R-T E R MM E D I U M-T E R ML O N G E R-T E R M

1.Illustrative only. The curves indicate the sequence and relative scale of expected market expansion, not forecast revenue

2.RUO is for “research use only” and limits the clinical claims that can be made and the payment options

3.IVD is an in vitro diagnostic and subject to country-specific product registrations, regulations and reimbursement processes

4.Profitability threshold determined on an annualizedbasis across all products with a blended ASP >$NZD 1,450. Actual breakeven will vary with payer mix, collection

rates, product mix and operating investment

PE GROUP profitability at

~55,000 tests/year

4

C U M U L A T I V E R E V E N U E

OUTLOOK: POSITIONED TO UNLOCK VALUE
FIRST MOVER; LARGE MARKET; BACKED BY EVIDENCE; KEY COMMERCIAL CATALYSTS

1st

First mover &

market leader

Urine-based, non-invasive

bladder cancer tests

US$10.6b

1

Global market

opportunity

Driven by ~7m US hematuria

patients a year

Grade A

AUA

2

evidence rating

Cxbladder Triage: the only

urine biomarker rated

‘Grade A’

Medicare LCD

Triage and Triage Plus - the only

tests covered by CMS in L40378

Coverage effective from 20

December 2026 for 71 million

US lives

Pricing

Improving sales force

unit economics

Triage Plus US$1,328; Triage

US$1,057; Monitor US$1,026

vs. US$760

3

on legacy

products

1.US$10.6b is a Pacific Edge estimate; see appendix for assumptions.

2.AUA: American Urological Association.

3.New Triage and Monitor prices provisional and subject to finalization; expected effective on 1 Jan 2027

15

Global commercial traction

Commercial payer and Medicare policy wins bring 78.6 million US lives under contract for hematuria evaluation;

volume growth and favorable prices drive APAC towards profitability on a direct cost basis

APPENDIX
16

PACIFIC EDGE IS FOUNDED ON DELIVERING POSITIVE OUTCOMES FOR SOCIETY
WE CREATE VALUE BY PRIORITISING OUR PATIENTS, OUR PHYSICIANS AND OUR PEOPLE

WE PUT PATIENTS FIRST IN EVERYTHING WE DO

•WE are committed to customer success

•WE are guided by data and evidence

•WE are trusting and transparent

•WE support our teammates

•WE celebrate successes, large and small

17

Our Mission

To help improve people’s lives and patient

outcomes by providing leading solutions for the

early detection and management of cancer

Our Vision

A world where the early diagnosis and better

treatment of cancer is within reach of everyone

PACIFIC EDGE – THE FIRST MOVER AND LEADER IN BLADDER CANCER DIAGNOSTICS
A GLOBAL COMPANY WITH A GLOBAL OPPORTUNITY

18

1.See slides 31 - 33 for assumptions

US$10.6b

1

Global Market Opportunity

Jan 2026
Kaiser RWE published

supporting Triage.

Largest ever UBB

1


hematuria study

May 2026

Novitas publishes

Draft LCD DL40378

with coverage for

Triage Plus and

Triage

Nov 2026

Novitas Final LCD;

effective 20 Dec 2026

Dec 2014

Launch of

Cxbladder

Triage

Nov 2023

Kaiser EMR

integration

goes live

Dec 2022

Lotan et al:

Enhanced

Cxbladder

Tests Deliver

Improved

Performance.

Journal of

Urology

Feb 2018

Cxb Triage

adopted into

Canterbury

Community Health

Pathways with

primary care

referral

2011

2011

Pacific Edge

Diagnostics

New Zealand

(PEDNZ)

established

2012

Dec 2012

Launch of Pacific Edge

Diagnostics USAand

Cxb Detect

2013

Mar 2013

First commercial

sale (Cxb Detect)

for PEDUSA

May 2013

First commercial

sale (Cxb Detect)

for PEDNZ

2014

2015

Dec 2015

Launch of

Cxbladder

Monitor

2016

2018

2019

2020

Jun 2020

Kaiser Permanente,

approves commercial

use of Cxbladder

Jul 2020

Medicare

reimbursement of

Cxbladderat

US$760/test

2021

Aug 2021

Cxbladder reaches

70% public

healthcare

coverage in NZ

2022

2023

2024

May 2024

STRATA podium

presentation at

AUA 2024.

Study published

in Journal of

Urology

TIMELINE: COMPANY MILESTONES

2025

Feb 2025

Triage included in AUA

Microhematuria

Guideline

Apr 2025

Medicare non-

coverage

effective

Nov 2025

Triage Plus gets CMS

draft price of

US$1,328

2026

1.UBBs are urine-based biomarkers – a term adopted by AUA in their guidelines

THE CXBLADDER SUITE: TRIAGE AND TRIAGE PLUS FOR HEMATURIA EVALUATION
TESTS TO RULE OUT BLADDER CANCER AND IDENTIFY THOSE MOST NEEDING SPECIALIST CARE

HEMATURIA EVALUATION

NEGATIVE RESULT

RULE OUT BLADDER CANCER

The test combines a High Negative Predictive Value with

High Sensitivity (it picks up most cancers)



POSITIVE RESULT

PRIORITIZE SPECIALIST CARE

The test combines a High Positive Predictive Value with

High Specificity (it delivers few false positives)


PERFORMANCEKavalieris et al. (2015)

1

•Sensitivity: 95%

•Specificity: 45%

•Negative Predictive Value: 99%

•Positive Predictive Value: N/A

Harvey et al. (2025)

2

•Sensitivity: 93.6%

*

•Specificity: 98.2%

**

•Negative Predictive Value: 99.4%

*

•Positive Predictive Value: 74.6%

**

WHEN IT IS USED: Prior to cystoscopy

Prior to cystoscopy / as an adjunct /

3 weeks post cystoscopy

COMMERCIALLY AVAILABLEGlobally availableGlobally available

AUA GUIDELINEGrade A EvidenceAssessment expected in 2027

MEDICAREUS$1,058

3

(Effective 20 December 2026)US$1,328 (Effective 20 December 2026)

20

1.Kavalieris et al. (2015) A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23.

2.Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739

3.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027

* When lower 0.15 cut point on test report is used

** When higher 0.54 cut point on test report is used

THE CXBLADDER SUITE: MONITOR AND SURVEILLANCE PLUS
ALTERNATIVE TO CYSTOSCOPY FOR NMIBC

1

PATIENTS UNDERGOING SURVEILLANCE FOR RECURRENCE


NMIBC

1

CANCER SURVEILLANCE RECURRENCE

NEGATIVE RESULT

RULE OUT BLADDER CANCER RECURRENCE

The test combines a High Negative Predictive Value

with High Sensitivity (it picks up most cancers)


•In development, showing improved

performance

PERFORMANCE

•Sensitivity: 93%

2,3

•Specificity: N/A

•Negative Predictive Value: 97%

2,3

•Positive Predictive Value: N/A

•Sensitivity: not yet published

•Specificity: not yet published

•Negative Predicative Value: not yet

published

•Positive Predictive Value: not yet

published

WHEN IT IS USED:

At any surveillance time point 9 months

after the most recent cancer diagnosis

At any surveillance time point after the

first surveillance cystoscopy (6 weeks)

COMMERCIALLY AVAILABLE

Globally available•USA: CPT-PLA code targeted for Jun

2027, reimbursement from Jan 2028

•APAC: Soft launch from Q2 FY28

GUIDELINES

NCCN

4

2bNot yet available for assessment

MEDICARE

US$1,026

5

(non-covered)Seeking US$1,800

6

(not yet covered)

21

1.NMIBC: non-muscle invasive bladder cancer

2.Kavalieris et al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426.

3.Lotan et al. (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8.

4.NCCN: National Comprehensive Cancer Network

5.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027

6.Seeking pricing by way of crosswalk

FY 26 FINANCIAL PERFORMANCE: POSITIONING FOR MEDICARE RE-COVERAGE
COST SAVINGS MINIMIZE CASH BURN; $36.1 MILLION CAPITAL RAISE IN MAY 2026 STRENGTHENS BALANCE SHEET

1.Net cash, cash equivalents and short-term deposits at the end of the period

22

Financial Period (NZ$M)

1H 26

(Unaudited)

2H 26

(Unaudited)

FY 26

(Audited)

FY 25

(Audited)

2H 26 vs 1H

26

FY 26 vs FY 25

Operating Revenue$5.9$5.6$11.5$21.8(6.4%)(47.4%)

Total Revenue$7.1$6.5$13.6$24.6(9.3%)(44.8%)

Operating Expenses$26.2$23.1$49.4$54.6(11.9%)(9.5%)

Net Loss After Tax($19.1)($16.7)($35.8)($30.0)(12.8%)19.5%

Cash Receipts from Customers$8.0$5.2$13.2$21.6(34.3%)(38.7%)

Net Cash Flows to Operating Activities($19.0)($12.9)($31.9)($24.7)(32.1%)29.1%

Net Cash

1

$22.1$7.8$7.8$22.6(64.8%)(65.5%)

Monthly Cash Burn $3.3$2.4$2.9$2.3(27.7%)23.4%

FINANCIAL PERFORMANCE OPERATING EXPENSES
ALL COSTS REDUCED WITH LARGEST REDUCTION IN SALES AND MARKETING


23

Financial Period (NZ$M)

1H 26

(Unaudited)

2H 26

(Unaudited)

FY 26

(Audited)

FY 25

(Audited)

2H 26 vs

1H 26

FY 26 vs

FY 25

Laboratory Operations $5.9$5.7$11.6$12.5(2.8%)(7.1%)

Research $7.1$6.4$13.4$14.6(9.9%)(8.2%)

Sales and Marketing $8.5$6.8$15.2$17.5(20.0%)(13.2%)

General Administration$4.8$4.3$9.1$9.9(11.8%)(8.1%)

Total operating expenses $26.2$23.1$49.4$54.6(11.9%)(9.5%)

PACIFIC EDGE’S EVIDENCE PROGRAM SEEKS TO CHANGE CLINICAL PRACTICE
Clinical Evidence

AV, CV, CU

HEALTHCARE PAYERS

(Medicare, Kaiser

Permanente, Veterans

Administration, private

payers, etc).

- Change Medical Policy

(practice)

- Change Reimbursement

Policy

PROFESSIONAL SOCIETIES

(AUA, EAU, NCCN)

- Change Standard of Care

Guidelines

Guidelines change:

- Healthcare Payer Medical

and Reimbursement

Policies

Guidelines change:

- Clinical Practice

UROLOGISTS - Change Clinical Practice

EVIDENCE DEVELOPED IN A STRUCTURED FRAMEWORK:

•Analytical Validity (AV): Evidence that a test is repeatable in the lab for a given indication and population

•Clinical Validity (CV): Evidence a test works in the same way on an independent eligible population for a given indication

•Clinical Utility (CU): Evidence that a test changes clinical practice in the hands of a physician; CU evidence obtained through randomized control trials can

provide a high level of support for guideline change (in addition to AV and CV evidence)

•Real World Evidence (RWE): CU verification of the real-world use of the test in clinical practice, usually through regular use of the test by physicians

AUDIENCE

EVIDENCE USE

24

Calendar year
Pre

2023

202320242025202620272028

Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2

STRATA

DRIVE

AUSSIE

microDRIVE

Pooled CV

CREDIBLE

HEMATURIA EVALUATION FIVE-YEAR CLINICAL STUDIES ROADMAP

*

*

*

*

*

Publication Submitted

Records review / follow-up

Database lock

Legend:

Pre-activation (docs, CTA etc)

SIV

Enrollment

Data Cleaning

*

DBL

DBL

DBL

25

Calendar year
Pre

2023

202320242025202620272028

Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2

“The 1800”

1

LOBSTER

OCTOPUS

*

SURVEILLANCE FIVE-YEAR CLINICAL STUDIES ROADMAP

26

Publication Submitted

Records review / follow-up

Database lock

Legend:

Business case approved

SIV

Enrollment

Data Cleaning

*

DBL

Scheduled surveillance visits

CAB

2

1.“The 1800” is the Surveillance Plus development dataset

2.CAB is the Pacific Edge Clinical Advisory Board. It was convened at SUO in Arizona to review and confirm the clinical study trial design for OCTOPUS

27
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS

COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES

Clinical Utility (CU) - Evidence a test that can usefully change patient management within the context of care for the defined population and indication Clinical Validity (CV) - Evidence a test works in

the same way on an independent eligible population for a given indication. Analytical validity (AV) - Evidence a test is repeatable in the lab for a given indication and population

STUDY

TEST AND EVIDENCE

PUBLICATION DATE

(1)

1. STRATA Clinical Utility

- CU of Triage

Published May 2024

2. Automated RNA & DNA extraction

- AV of Triage, Detect and Monitor

Published September 2024

3. Triage Plus Analytical Validation

- AV of Triage Plus

Published July 2025

4. DRIVE Clinical Validation

- CV of Triage Plus

Published October 2025

5. STRATA second publication

- CU of Triage

Q3 2027

6. AUSSIE Clinical Validation

- CVof Triage Plus

Published October 2026

7. microDRIVE Clinical Validation

- CV of Triage Plus

Q1 2027

8. Surveillance Plus Analytical Validation

- AV of Surveillance Plus

Q2 2027

9. Pooled Analysis MH & GH Clinical Validation

2

- CV of Triage Plus

Q3 2027

10. LOBSTER Clinical Validation

- CV of Monitor/Surveillance Plus

Q3 2027

11. CREDIBLE Clinical Utility

- CU of Triage Plus

Q1 2028

12. OCTOPUS Clinical Utility

- CU Surveillance Plus

No timeline at this point

1

All dates are calendar year and our best current estimates

2

The MH and GH pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE

Already published evidence

Expected to be published before AUA microhematuria guideline committee initiates next literature review in Q3 2027

INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO
HIGH IMPACT RESEARCH AT LOW COST

1.All dates are calendar year and our best current estimates. Timelines are controlled by the investigator

2.Filson et al (2026); Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study, Urology Practice® (2026), doi:

10.1097/UPJ.0000000000000972.

3.BCG: Bacillus Calmette–Guérin is a bacterium instilled into the bladder that triggers an immune response that targets and destroys cancer cells.

4.MIBC: Muscle Invasive Bladder Cancer

INDEPENDENT STUDY FOCUSINSTITUTIONTEST AND EVIDENCE TYPE

PUBLICATION

DATE

1

Real World Utility of Triage in MH: A Matched

Cohort Study

Kaiser Permanente, USCU Triage (RWE)Q1 2026

2

Patient preference and satisfaction of

“biomarkers vs cystoscopy”

Mayo Clinic, USCU MonitorQ4 2026

NZ Hematuria Pathway comparing T/D with

Triage Plus on AUSSIE samples

Canterbury DHBCU of Triage PlusQ1 2027

Retrospective comparison of Triage and Triage

Plus in the Kaiser System

Kaiser Permanente, USCU Triage Plus2027

Test utility in screening patients at risk for

bladder cancer

UT Southwestern, USCU Triage Plus 2027

Test utility in assessing therapy success in a

reduced chemotherapy protocol for upper tract

tumors

Israel Institute of

Technology, Israel

CU Monitor

CU Surveillance Plus

2027

Test utility in assessing response to BCG

3

in high-

grade bladder cancer patients

University of Miami, US

CU Monitor

CU Surveillance Plus

2027

Test utility for the surveillance of MIBC

4

treated

with bladder sparing methods (PRESERVE Trial)

Cleveland Clinic, US

CU Monitor

CU Surveillance Plus

2028

A Randomized Trial of Apalutamide in Non-

Muscle Invasive Bladder Cancer

National Institutes of

Health, US

CU Monitor

CU Surveillance Plus

2029

Already published evidence

28

•Investigator initiated trials (IITs) are

independent studies in which Pacific Edge

typically provides free testing, so provide

significant value at low cost

•IITs extend the evidence portfolio for new

indications of existing tests and may inform

new ‘core’ clinical trials

•IITs are an important part of Key Opinion

Leader (KOL) engagement and generate

publications or podium presentations that

give profile to Cxbladder and Pacific Edge

BACKGROUND ON NMIBC AND MIBC
•Bladder Cancer

•An estimated 83,190 patients were diagnosed with bladder cancer in the USA in 2024 at an average age of 73

1

•Non-muscle invasive Bladder Cancer (NMIBC)

•NMIBC tumors represent approximately 75% of the bladder cancer diagnoses each year (CIS, Ta and T1)

•NMIBC tumors are localized and present on the lining of the bladder wall and shed cancer cells and cell-free DNA/RNA into the urine in the bladder

•NMIBC tumors are highly treatable with surgery/resection and deemed cancer free after surgery/resection

•NMIBC patients are placed on a surveillance protocol after surgery/resection, because recurrence can be 50-70% within the first two years

2

•NMIBC → TURBT → Surveillance

•Muscle-invasive Bladder Cancer (MIBC)

•MIBC tumors represent approximately 25% of the bladder cancer diagnoses each year (T2-4)

•MIBC tumors differ from NMIBC tumors, because they shed cells/nucleotides to the blood

•MIBC patients have advanced/serious disease, require high-levels of intervention (radical cystectomy followed by multiple therapies)

•MIBC patients are not deemed cancer free after cystectomy and frequently monitored for residual and metastatic disease

•MIBC → Cystectomy → Monitoring

1.American Cancer Society. Cancer Facts & Figures 2024

2.Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of

non-muscle invasive bladder cancer: AUA/SUO guideline: 2024

amendment. J Urol. 2024;10.1097/JU.0000000000003846.

NMIBC STANDARD OF CARE: INTERVENTION AND SURVEILLANCE
•NMIBC Standard of Care – Intervention

•After NMIBC diagnosis, the standard intervention is a Trans-Urethral Resection of a Bladder Tumor (TURBT)

•TURBT involves inserting a camera into the urethra and the use of small instruments like a wire loop or laser to cut or burn away the tumor tissue

•Patients are deemed cancer free post TURBTwhen muscles and tumor margins are confirmed free of disease by pathology

•A resection biopsy taken during surgery is used to stage the tumor (T0, Ta, CIS, T1-4) and determine the grade (low or high grade) which also

provides the risk of recurrence.

•All NMIBC patients are then classified into risk categories based on this information (low, intermediate and high risk).

•NMIBC Standard of Care - Surveillance

•BCG (bacillus calmette guérin) is administered for several weeks after TURBT to initiate an immune response towards the tumor. Some

patients are ‘non-responders’

•A cystoscopy at 3 months is recommended for every patient

•Following the 3-month cystoscopy, patients are recommended for routine surveillance protocols involving cystoscopy and imaging among

others based on their risk category

•Due to the high burden of these protocols, the average patient only stays on surveillance for1.8 years not 5

1

as recommended by most

guidelines

1.AUA AQUA Registry

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (US)
31

REGIONSTATISTICSOURCE

UNITED STATES

Population 341,762,685https://www.census.gov/popclock/

Incidence of hematuria7,000,000

Presentation from Dr Sia Daneshmand (Director of

Urologic Oncology and Clinical Research, USC) July 2019

Referred for clinical workup3,500,000

Presentation from Dr Sia Daneshmand (Director of

Urologic Oncology and Clinical Research, USC) July 2019

Proportion of gross hematuria amongst

those referred for clinical workup700,000Pacific Edge estimate

Proportion of microhematuria amongst

those referred for clinical workup2,800,000Pacific Edge estimate

Proportion of low-risk microhematuria 200,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Proportion of intermediate-risk

microhematuria 1,140,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Proportion of high-risk microhematuria 1,460,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Annual cases of bladder cancer 84,870

National Cancer Institute

Patients living with bladder cancer 744,044

National Cancer Institute

Test opportunities 4,616,066Pacific Edge estimate

Price of Cxbladder (US$)

$1,328 for Cxbladder Triage Plus, $1,800 for Cxbladder

Surveillance Plus

Surveillance Plus is a target price sought by crosswalk

and has not yet been established or covered

TAM (US$billion)$6.7

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (EUROPE)
32

REGIONSTATISTICSOURCE

EUROPE (EXCLUDING

RUSSIA)

Population

600,000,000World-population - Europe

World-population - Russia

Incidence of hematuria12,000,000

Science Direct

Referred for clinical workup6,000,000

Presentation from Dr Sia Daneshmand (Director of

Urologic Oncology and Clinical Research, USC) July 2019

Proportion of gross hematuria amongst

those referred for clinical workup1,200,000Pacific Edge estimate

Proportion of microhematuria amongst

those referred for clinical workup4,800,000Pacific Edge estimate

Proportion of low-risk microhematuria 340,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Proportion of intermediate-risk

microhematuria 1,960,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Proportion of high-risk microhematuria 2,500,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

Pacific Edge estimates to account for AUA 2025

guidelines

Annual cases of bladder cancer 180,000

Uroweb

Patients living with bladder cancer 900,000Pacific Edge estimate - 5 years of annual cases

Test opportunities 7,350,000Pacific Edge estimate

Price of Cxbladder EURO€245Pacific Edge estimate

TAM (US$billion)$2.0

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (APAC)
33

REGIONSTATISTICSOURCE

APAC (EXCLUDING INDIA

AND CHINA)

Population

830,000,000

World population - Southeast Asia

Population Pyramid - Japan

Population Pyramid - Hong Kong

Incidence of hematuria16,600,000

Science Direct

Referred for clinical workup

8,300,000

Presentation from Dr Sia Daneshmand (Director of

Urologic Oncology and Clinical Research, USC) July 2019

Proportion of gross hematuria amongst

those referred for clinical workup

1,660,000

Pacific Edge estimate

Proportion of microhematuria amongst

those referred for clinical workup

6,640,000

Pacific Edge estimate

Proportion of low-risk microhematuria

470,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

AUA 2025 guidelines

Proportion of intermediate-risk

microhematuria

2,710,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

AUA 2025 guidelines

Proportion of high-risk microhematuria

3,460,000

Woldu, S, et al. Evaluation of the New American Urological

Association Guidelines Risk Classification for Hematuria;

AUA 2025 guidelines

Annual cases of bladder cancer

58,000

WHO

Hong Kong

Patients living with bladder cancer 290,000Pacific Edge estimate - 5 years of annual cases

Test opportunities 3,494,000Pacific Edge estimate

Price of Cxbladder (US$)$550Pacific Edge estimate

TAM (US$billion)$1.9

KEY CLINICAL ADVISORS AND CONSULTANTS
Associate Professor Katie Murray, DOMS, FACS

Institution: NYU Langone

Relationship: Consultant, CAB member,

Brief Bio: Published >80 articles. Deputy Editor for J Urol.

Leadership roles for SUO Young Urologic Oncology Clinical Trials

Professor Jonathan Wright, MD, MS, FACS

Institution: Fred Hutchinson Cancer Center at UW

Relationship: Consultant, CAB member, CT PI

Brief Bio: Member of ACS, SUO, AUA

Professor Wade Sexton, MD

Institution: University of South Florida & Moffitt Cancer Center

Relationship: Consultant, CAB member

Brief Bio: Published >100 articles. NCCN Bladder Cancer

Guidelines, AUA Annual Board Review Course

Professor Jay Raman, MD

Institution: Penn State and Hershey Medical Center

Relationship: Consultant, CAB member, CT PI

Brief Bio: Published >350 articles. Chair of AUA Office of Education

and Past-President of the Mid-Atlantic AUA section. Urology

Advisory Council for ACS, Hematuria Guidelines member

Associate Professor Kristen Scarpato, MD, MPH, FACS

Institution: Vanderbilt University Medical Center

Relationship: Consultant, CAB member, CT PI

Brief Bio: SUO Education Committee, AUA Core Curriculum,

Urology Practice Editorial Committee

Professor Yair Lotan, MD

Institution: UT Southwestern Medical Center

Relationship: Consultant, CAB member, IIT PI, CT PI

Brief Bio: Published >500 articles. Contributor to AUA/ASCO/ASTRO

MIBC and Hematuria Guidelines. Chair of AUA Core Curriculum. BCAN

Adboard

Professor Sam Chang, MD, MBA

Institution: Vanderbilt Cancer Center

Relationship: Consultant, CAB member

Brief Bio: Published >200 articles. Chair of AUA NMIBC Guidelines,

SUO Executive Board, ABU/AUA Examination Committee, BCAN

Adboard, AUA representative to the AJCC

Assistant Professor John Sfakianos

Institution: Icahn School of Medicine at Mount Sinai

Relationship: Consultant, CAB member

Brief Bio: Published >20 articles. Reviewer for J Urol and Urologic

Oncology

Professor Dan Barocas, MD, MPH, FACS

Institution: Vanderbilt University Medical Center

Relationship: Consultant, CAB member

Brief Bio: Published >100 articles. AUA Guidelines panel for

microscopic hematuria. Reviewer for AUA educational materials

Associate Professor, Siamak Daneshmand, MD

Institution: Keck School of Medicine at USC

Relationship: Consultant, CAB member, CT PI

Brief Bio: Published >200 articles. Editorial board of the J Urol,

Bladder Cancer Journal, Current Opinions in Urology, BCAN Adboard,

AUA/SUO Guideline Committee on NMIBC

ASCO: American Society of Clinical Oncology

ASTRO: American Society of Radiation Oncology

AUA: American Urological Association

BCAN: Bladder Cancer Advocacy Network

CAB: Clinical Advisory Board

CT PI: Clinical Trials Principal Investigator

FACS: Fellow of the American College of Surgeons

IIT PI: Investigator Initiated Trial Principal Investigator

J Urol: Journal of Urology

KOL: Key Opinion Leader

MPH: Master of Public Health

SUO: Society of Urologic Oncology

34

OUTLOOK: POSITIONED TO UNLOCK VALUE
MULTIPLE COMMERCIAL, CLINICAL AND INNOVATION CATALYSTS

LONG-TERM VALUE CREATION

RESEARCH INNOVATION

MEDIUM-TERM VALUE CREATION

CLINICAL EVIDENCE GENERATION

NEAR-TERM VALUE CREATION

COMMERCIAL CATALYSTS

•Case-by-case reimbursement for Triage

and Triage Plus under draft LCD, with first

Novitas payments received

•New LCD effective from 20 Dec 2026

•US customers adopt Triage Plus at

US$1,328/test

•Building US Commercial payer medical

policy momentum

•Evidence generation program delivers

sustained strategic value

•US commercial payer policy for Triage

and Triage Plus drives test adoption

•AUA guideline review (2027/28)

expected to expand serviceable market

•Investigator initiated trials (IITs) generate

novel evidence for new indications

•Triage Plus and Surveillance Plus deliver

better patient outcomes at higher

margin pricing for improved unit

economics

•SurveillancePlus CPT-PLA coding

submission in June 2027 and claim-by-

claim revenue from Jan 1, 2028

•Seeking US$1,800 CMS pricing for

Surveillance Plus in FY28

•Product simplification and kitted IVD

products enable de-centralized

deployment in international markets

35

INDEPENDENT DIRECTORS
SARAH PARK

ANATOLE MASFEN

BRYAN WILLIAMS

ANNA STOVE

TONY BARCLAY

SIMON FLOOD

Chairman

Simon has spent more than 25

years in the global investment

management industry having held

senior Investment and Business

Leadership roles in some of the

world’s pre-eminent investment

management firms including

Merrill Lynch Investment Managers

Lion Global Investors and AXA

Investment Managers

DR PETER MEINTJES

Chief Executive Officer

Peter is a molecular diagnostics and

genomics leader focused on

nascent market development of

disruptive innovations to drive

commercial success. Prior to joining

Pacific Edge, he was based in

Boston in a succession of diagnostic

leadership roles. Most recently he

was the Chief Commercial Officer

at Eurofins Transplant Genomics

and before that he was CEO at

Omixon

SENIOR LEADERSHIP TEAM

GRANT GIBSON DR TAMER ABOUSHWAREB DR JUSTIN HARVEY

Chief Financial Officer Chief Medical Officer Chief Technology Officer

GLEN COSTIN DARRELL MORGAN ZOE O’DONNELL

President Asia Pacific Chief Operating Officer Global Head of People & Culture

PROFESSOR PARRY GUILFORD WILLY IGLESIAS

Chief Scientific Officer Chief Digital Officer

PACIFIC EDGE BOARD AND MANAGEMENT

36

FOR MORE INFORMATION:
Dr. Peter Meintjes

Chief Executive Officer

email: peter.meintjes@pelnz.com

Grant Gibson

Chief Financial Officer

email: grant.gibson@pelnz.com

Pacific Edge

87 St David Street, PO Box 56, Dunedin, New Zealand

P +64 3 577 6733 Within NZ 0800 555 563

email: investors@pacificedge.co.nz

www.pacificedgedx.com

37

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • PHL — Promisia Healthcare Limited: ASM 2026 Presentation
    2026-08-27

    “26 Disclaimer This presentation has been prepared by Promisia Healthcare Limited (“PHL”). The information in this presentation is of a general nature only. It is not a complete description of PHL. This presentation is not a recommendation or offer of financial products for subsc…”

  • BPG — Black Pearl Group Limited: Q2 FY27 Investor Webinar
    2026-10-15

    “BLACKPEARL GROUP | INVESTOR ANNOUNCEMENT 15 OCTOBER 2026 Q2 FY27 Investor Webinar Blackpearl Group Limited (NZX/ASX: BPG) advises that it will host an investor webinar at 12.30pm NZDT / 10.30am AEDT on Tuesday, 20 October 2026, following the release of its Q2 FY27 update.…”

  • BPG — Black Pearl Group Limited: Amended FY26 Annual Report and Presentation
    2026-09-10

    “BLACKPEARL GROUP | INVESTOR ANNOUNCEMENT 11 SEP 2026 Amended FY26 Annual Report and Investor Presentation Blackpearl Group Limited (NZX/ASX: BPG) attaches amended versions of its FY26 Annual Report and Investor Presentation, released to the market on 28 May 2026. T…”